Kantonsspital St.Gallen
login

publications

Jens Huober

title  
 
Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J U, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch F J, Lederer B, Gerber B, Zahm D M, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching P A. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 145:44-52.
   
Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert U S, Banys-Paluchowski M, Bauerfeind I, Blohmer J U, Budach W, Dall P, Fallenberg E M, Fasching P A, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M P, Maass N, Mundhenke C, Nitz U, Park-Simon T W, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H P, Solbach C, Solomayer E F, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:214-227.
   
Thill M, Friedrich M, Kolberg-Liedtke C, Albert U S, Banys-Paluchowski M, Bauerfeind I, Blohmer J U, Budach W, Dall P, Fallenberg E M, Fasching P A, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M P, Maass N, Mundhenke C, Nitz U, Park-Simon T W, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H P, Solbach C, Solomayer E F, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:228-235.
   
Johnston S, O'Shaughnessy J, Martín M, Huober J, Toi M, Sohn J, Andre V A M, Martin H R, Hardebeck M C, Goetz M P. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer 2021; 7:80.
   
Venet D, Rediti M, Maetens M, Fumagalli D, Brown D N, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021;.
   
Friedl T W P, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker S Y, Heinrich G, Häberle L, Fasching P A, Beckmann M W, Coleman R E, Janni W, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
   
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J U, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E F, Schmitt W D, Hanusch C, Fasching P A, Lübbe K, Solbach C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B V, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
   
Schneeweiss A, Ettl J, Lüftner D, Beckmann M W, Belleville E, Fasching P A, Fehm T N, Geberth M, Häberle L, Hadji P, Hartkopf A D, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H C, Kurbacher C M, Klein E, Lux M P, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F A, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker S Y. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast 2021; 55:138-139.
   
Vathiotis I A, Moutafi M K, Divakar P, Aung T N, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim S B, Harbeck N, Gomez H, Shafi S, Syrigos K N, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm D L. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clin Cancer Res 2021;.
   
Filho O M, Stover D G, Asad S, Ansell P J, Watson M, Loibl S, Geyer C E, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo H S, Huober J, Golshan M, Sikov W M, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans W F. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
   
Chic N, Luen S J, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Láng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021;.
   
Untch M, Fasching P A, Brucker S Y, Budach W, Denkert C, Haidinger R, Huober J, Jackisch C, Janni W, Kolberg-Liedtke C, Krug D, Kühn T, Loibl S, Lüftner D, Müller V, Schneeweiss A, Thill M, Harbeck N, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021; 81:637-653.
   
Rugo H S, Huober J, García-Sáenz J A, Masuda N, Sohn J H, Andre V A M, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26:e522.
   
Villegas S L, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H U, Fasching P A, Weber K E, Albig C, Heinrichs C, Marme F, Hartmann A, Hanusch C, Schmitt W D, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B V, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
   
Jhaveri K, Juric D, Yap Y S, Cresta S, Layman R M, Duhoux F P, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021;.
   
Möbus V, Lück H J, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E M, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J U, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B V, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, GBG and AGO-B . Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
   
Schulz S V W, Schumann U, Otto S, Kirsten J, Treff G, Janni W, Huober J, Leinert E, Steinacker J M, Bizjak D A. Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences. Disabil Rehabil 2021;1-8.
   
Rugo H S, Huober J, García-Sáenz J A, Masuda N, Sohn J H, Andre V A M, Barriga S, Cox J, Goetz M. In Reply. Oncologist 2021; 26:e1286-e1287.
   
Marme F, Solbach C, Michel L, Schneeweiss A, Blohmer J U, Huober J, Fasching P A, Jackisch C, Nekljudova V, Link T, Rhiem K, Rey J, Denkert C, Hanusch C, Tesch H, Lederer B, Loibl S, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153:203-212.
   
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J U, Zahm D M, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P A, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer 2020; 8:.
   
Schneeweiss A, Ettl J, Lüftner D, Beckmann M W, Belleville E, Fasching P A, Fehm T N, Geberth M, Häberle L, Hadji P, Hartkopf A D, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H C, Kurbacher C M, Klein E, Lux M P, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F A, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker S Y. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
   
Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, Müller V, Albert U S, Banys-Paluchowski M, Bauerfeind I, Blohmer J U, Budach W, Dall P, Diel I, Fallenberg E M, Fasching P A, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe H H, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Moebus V, Mundhenke C, Park-Simon T W, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Solbach C, Solomayer E F, Stickeler E, Thomssen C, Witzel I, Wöckel A, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020; 15:294-309.
   
Karn T, Meissner T, Weber K E, Solbach C, Denkert C, Engels K, Fasching P A, Sinn B V, Schrader I, Budczies J, Marme F, Müller V, Holtrich U, Gerber B, Schem C, Young B M, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
   
Johnston S R D, Harbeck N, Hegg R, Toi M, Martín M, Shao Z M, Zhang Q Y, Martinez Rodriguez J L, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortes J, Huober J, Wardley A, Tolaney S M, Cicin I, Smith I C, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators . Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38:3987-3998.
   
Huebner H, Kurbacher C M, Kuesters G, Hartkopf A D, Lux M P, Huober J, Volz B, Taran F A, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Ruebner M, Untch M, Fasching P A, Janni W, Fehm T N, Kolberg H C, Wallwiener D, Brucker S Y, Schneeweiss A, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer 2020; 20:1091.
   
Goetz M P, Martín M, Tokunaga E, Park I H, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford M C, Price G L, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020; 25:e1346-e1354.
   
Bekes I, Eichler M, Singer S, Friedl T W P, Harbeck N, Rack B, Forstbauer H, Dannecker C, Huober J, Kiechle M, Lato K, Janni W, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
   
Bizjak D A, Schulz S V W, Schumann U, Otto S, Kirsten J, Ebner F, Leinert E, Huober J, Janni W, Steinacker J M. Beneficial Molecular Adaptations In -Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study. Cancers (Basel) 2020; 12:.
   
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers F S, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud F G, Iorio M V, Verderio P, Daidone M G. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int J Mol Sci 2020; 21:.
   
Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching P A, Kolberg H C, Schulmeyer C E, Welslau M, Overkamp F, Fehm T N, Lux M P, Schneeweiss A, Lüftner D, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80:1115-1122.
   
Rugo H S, Huober J, García-Sáenz J A, Masuda N, Sohn J H, Andre V A M, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2020; 26:e53-e65.
   
Hamilton E, Cortes J, Ozyilkan O, Chen S C, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Chapman S C, Lu Y, Hardebeck M C, Bear M M, Johnston E L, Martín M. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer 2020;.
   
Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi M A, De Santis M C, Saura C, Huober J, Fumagalli D, Izquierdo M, Piccart M, Daidone M G, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
   
Michel L L, Hartkopf A D, Fasching P A, Kolberg H C, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F A, Lux M P, Wallwiener D, Brucker S Y, Schneeweiss A, Fehm T N. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12:.
   
Fasching P A, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt W D, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R K, Hahnen E, Untch M, Burchardi N, Blohmer J U, Loibl S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast . Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2020; 32:49-57.
   
Karn T, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober J, Becker C, Blohmer J U, Marmé F, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020; 31:1216-1222.
   
Lüftner D, Schneeweiss A, Hartkopf A D, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching P A, Kolberg H C, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm T N, Lux M P. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd 2020; 80:391-398.
   
Schneeweiss A, Hartkopf A D, Müller V, Wöckel A, Lux M P, Janni W, Ettl J, Belleville E, Huober J, Thill M, Fasching P A, Kolberg H C, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm T N, Lüftner D, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020; 80:277-287.
   
Huober J, Schneeweiss A, Hartkopf A D, Müller V, Lux M P, Janni W, Ettl J, Belleville E, Thill M, Fasching P A, Kolberg H C, Schulmeyer C E, Welslau M, Overkamp F, Tesch H, Fehm T N, Lüftner D, Schütz F, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80:1105-1114.
   
Werutsky G, Untch M, Hanusch C, Fasching P A, Blohmer J U, Seiler S, Denkert C, Tesch H, Jackisch C, Gerber B, Schneeweiss A, Link T, Krug D, Huober J, Rhiem K, Kühn T, Vladimirova V, Nekljudova V, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer 2020; 130:92-101.
   
De Gregorio A, Nagel G, Möller P, Rempen A, Schlicht E, Fritz S, Flock F, Kühn T, Thiel F, Felberbaum R, Ebner F, De Gregorio N, Friedl T W P, Wiesmüller L, Kuhn P, Schmitt M, Janni W, Rothenbacher D, Huober J. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. Arch Gynecol Obstet 2019; 301:273-281.
   
Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert U S, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching P A, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M P, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H P, Solbach C, Solomayer E F, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:224-245.
   
Schochter F, Friedl T W P, deGregorio A, Krause S, Huober J, Rack B, Janni W. Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells 2019; 8:.
   
Thill M, Jackisch C, Janni W, Müller V, Albert U S, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching P A, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe H H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M P, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H P, Solbach C, Solomayer E F, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:247-255.
   
Witzel I, Loibl S, Wirtz R, Fasching P A, Denkert C, Weber K, Lück H J, Huober J, Karn T, Mackelenbergh M v, Marme F, Schem C, Stickeler E, Untch M, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer 2019; 121:1009-1015.
   
Hanker A B, Garrett J T, Estrada M V, Moore P D, Ericsson P G, Koch J P, Langley E, Singh S, Kim P S, Frampton G M, Sanford E, Owens P, Becker J, Groseclose M R, Castellino S, Joensuu H, Huober J, Brase J C, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga C L. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2019; 25:1434.
   
Laakmann E, Witzel I, Fasching P A, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm D M, Blohmer J U, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
   
Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D, Boccalini G, Vitale S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019; 11:1758835919891608.
   
Golshan M, Wong S M, Loibl S, Huober J, O'Shaughnessy J, Rugo H S, Wolmark N, Ansell P, Maag D, Sullivan D M, Metzger-Filho O, von Minckwitz G, Geyer C E, Sikov W M, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol 2019; 46:223-228.
   
Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P A, Gerber B, Bauerfeind I, Nitz U, Lück H J, Hanusch C, Thomssen C, Untch M, Nekljudova V, Mehta K, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer 2019; 26:826-834.
   
Rothé F, Silva M J, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson S J, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res 2019; 25:3581-3588.
   
Loibl S, Untch M, Burchardi N, Huober J, Sinn B V, Blohmer J U, Grischke E M, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279-1288.
   
Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker S Y, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg H C, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching P A, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd 2019; 79:591-604.
   
Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio M V, Hilbers F, de Azambuja E, de la Pena L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud F G, Apolone G, Verderio P, Daidone M G. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clin Cancer Res 2019; 25:3887-3895.
   
De Gregorio A, Widschwendter P, Ebner F, Friedl T W P, Huober J, Janni W, De Gregorio N. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB. Oncology 2019; 98:91-97.
   
de Gregorio N, de Gregorio A, Ebner F, Friedl T W P, Huober J, Hefty R, Wittau M, Janni W, Widschwendter P. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet 2019; 300:161-168.
   
Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena J C, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R D, Piccart-Gebhart M, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
   
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching P A, Just M, Hanusch C, Hackmann J, Blohmer J U, Rhiem K, Schmitt W D, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019; 37:2226-2234.
   
Huober J, Bartsch R, Marme F, Pagani O, Thomssen C. Luminal Metastatic Breast Cancer. Breast Care (Basel) 2019; 14:99-101.
   
Lüftner D, Bauerfeind I, Braun M, Brucker S Y, Fasching P A, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg H C, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019; 14:315-324.
   
Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L d l, Daidone M G, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F G, Apolone G, Verderio P, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019; 118:1-9.
   
Kolberg H C, Schneeweiss A, Fehm T N, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M P, Janni W, Hartkopf A D, Taran F A, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching P A, Brucker S Y. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd 2019; 79:470-482.
   
Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J U, Costa S D, Denkert C, Ditsch N, Gerber B, Hanusch C, Heil J, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019; 26:3892-3901.
   
Sinn B V, Weber K E, Schmitt W D, Fasching P A, Symmans W F, Blohmer J U, Karn T, Taube E T, Klauschen F, Marme F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019; 21:142.
   
Powles R L, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
   
Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P U, Albert U S, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe H H, Knoefel W T, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch H H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn H P, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M W, Blohmer J, Fasching P A, Lux M P, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H J, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:927-948.
   
Loibl S, O'Shaughnessy J, Untch M, Sikov W M, Rugo H S, McKee M D, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo J J, Metzger Filho O, Rastogi P, Symmans W F, Liu X, Geyer C E. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19:497-509.
   
Fasching P A, Loibl S, Hu C, Hart S N, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa S D, Blohmer J U, Fehm T, Huober J, Liedtke C, Weinshilboum R M, Wang L, Ingle J N, Müller V, Nekljudova V, Weber K E, Rack B, Rübner M, von Minckwitz G, Couch F J. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
   
De Gregorio A, Widschwendter P, Albrecht S, De Gregorio N, Friedl T W P, Huober J, Janni W, Ebner F K. Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital. Geburtshilfe Frauenheilkd 2018; 78:1138-1145.
   
Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer J U, Rezai M, Frank M, Engels K, Rhiem K, Fasching P A, Nekljudova V, von Minckwitz G, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
   
Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P A, Tesch H, Eggemann H, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J U, Hauschild M, Fehm T, Nekljudova V, Loibl S, GBG and the AGO-B Study Group . Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
   
Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers F S, Schuehly U, Korde L, Azim H A, Di Cosimo S, Tenglin R C, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber R D, de Azambuja E, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2018; 125:307-316.
   
Lux M P, Nabieva N, Hartkopf A D, Huober J, Volz B, Taran F A, Overkamp F, Kolberg H C, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P A, Janni W, Fehm T N, Wallwiener D, Schneeweiss A, Brucker S Y. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11:.
   
Loibl S, Weber K, Huober J, Krappmann K, Marme F, Schem C, Engels K, Pfitzner B M, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res 2018; 24:3358-3365.
   
Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P U, Jírů-Hillmann S, Albert U S, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe H H, Knoefel W T, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch H H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn H P, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M W, Blohmer J, Fasching P, Lux M P, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H J, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
   
Möbus V, Jackisch C, Lück H J, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum I B, Hinke A, Konecny G E, Untch M, Kurbacher C, AGO Breast Study Group (AGO-B) . Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
   
Schulz S V W, Laszlo R, Otto S, Prokopchuk D, Schumann U, Ebner F, Huober J, Steinacker J M. Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil 2017; 40:1501-1508.
   
Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker S Y, Dall P, Denkert C, Fasching P A, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd 2017; 77:633-644.
   
Ettl J, Huober J, Lüftner D, Marme F, Würstlein R. CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) 2017; 12:118-120.
   
Villegas S L, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner B M, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187.
   
Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im Y H, Borrego M R, Chen D R, Rodeheffer R, Piccart M, Suter T, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 2017; 168:631-638.
   
Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P A, Blohmer J U, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler R K. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3:1378-1385.
   
Nitz U, Gluz O, Huober J, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
   
Polasik A, Tzschaschel M, Schochter F, De Gregorio A, Friedl T W P, Rack B, Hartkopf A, Fasching P A, Schneeweiss A, Müller V, Huober J, Janni W, Fehm T. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?. Geburtshilfe Frauenheilkd 2017; 77:1291-1298.
   
Möbus V, von Minckwitz G, Jackisch C, Lück H J, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups . German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
   
Hanker A B, Garrett J T, Estrada M V, Moore P D, Ericsson P G, Koch J P, Langley E, Singh S, Kim P S, Frampton G M, Sanford E, Owens P, Becker J, Groseclose M R, Castellino S, Joensuu H, Huober J, Brase J C, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga C L. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017; 23:4323-4334.
   
Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von Minckwitz G, Untch M, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 2017; 23:5384-5393.
   
Goetz M P, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park I H, Trédan O, Chen S C, Manso L, Freedman O C, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith I C, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638-3646.
   
van Mackelenbergh M T, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P A, Blohmer J U, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K E, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat 2017; 167:59-71.
   
Reinisch M, Huober J, von Minckwitz G, Blohmer J U, Denkert C, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Rhiem K, Lederer B, Untch M, Nekljudova V V, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast 2017; 32:73-78.
   
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B I, Weber K E, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W D, Blohmer J U, Karn T, Pfitzner B M, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P A, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2017; 19:40-50.
   
Kümmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer J U, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C, Schneeweiss A, Denkert C, Engels K, Klare P, Fasching P A, von Minckwitz G, Burchardi N, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer 2017; 84:1-8.
   
Lux M P, Janni W, Hartkopf A D, Nabieva N, Taran F A, Overkamp F, Kolberg H C, Hadji P, Tesch H, Ettl J, Huober J, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Fehm T N, Wallwiener D, Brucker S Y, Schneeweiss A, Fasching P A. Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe Frauenheilkd 2017; 77:1281-1290.
   
Di Cosimo S, Campbell C, Azim H A, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng W M J, Colleoni M, Ferro A, Naume B J, Patel A, Huober J, Piccart-Gebhart M J, Baselga J, De Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer 2017; 89:42-48.
   
Fumagalli D, Venet D, Ignatiadis M, Azim H A, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang T W, Coccia-Portugal M A, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J C, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
   
Hartkopf A D, Huober J, Volz B, Nabieva N, Taran F A, Schwitulla J, Overkamp F, Kolberg H C, Hadji P, Tesch H, Häberle L, Ettl J, Lux M P, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P A, Janni W, Fehm T N, Wallwiener D, Brucker S Y, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
   
Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
   
Baselga J, Lewis Phillips G D, Verma S, Ro J, Huober J, Guardino A E, Samant M K, Olsen S, de Haas S L, Pegram M D. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2016; 22:3755-63.
   
von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators . Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
   
Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl T W P, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
   
 
page 1 2 3 of 3